In Brief: Rhone-Poulenc Rorer's Dilacor XR
Rhone-Poulenc Rorer's Dilacor XR: Once-daily calcium channel blocker approved for use in angina March 2. Dilacor XR (diltiazem) using Jago's Geomatrix controlled-release system has been available for treatment of hypertension since June 1992. Sales in 1994 totaled $128 mil. RPR notes that "angina and hypertension patients who are treated with other formulations of diltiazem can, with appropriate monitoring and titration, safely be switched to Dilacor XR capsules at the nearest equivalent total dose." Dilacor XR now has the same indications as Marion Merrell Dow's Cardizem CD...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth